Figure S2
Genome-wide false positive rate for GWAS based on different genotyping strategies. Genome-wide false positive rate (y-axis) was calculated as the number of simulations with at least one false positive divided by the total number of simulations at a Pvalue threshold (x-axis). Shown are the results and 95% confidence interval from 1,000 simulations based on the UK10K-WGS data under the null hypothesis where the phenotypes are generated from N(0,1) without any genetic effect. The red dashed line represents a genome-wide false positive rate of 0.05. Genome−wide false positive rate
Figure S4 Inflated false positive rate (FPR) in rare variant associations due to skewed phenotype distribution under the alternative. We have shown in the figure above (Fig. S1 ) that FPR can be inflated if the phenotype is not normally distributed under the null that there is no genetic effect. Here, we show that even if the residuals are normally distributed, the FPR can also be inflated if there is a rare variant of relatively large effect. Shown are the genome-wide false positive rate (GWFPR, total number of simulations with at least one false positive divided by the total number of simulations) before and after inverse normal transformation (INF), at a range of P-value thresholds. The phenotypes were simulated under an alternative hypothesis (q 2 = 0.02) using variants on chromosome 22, and the GWAS analysis was performed for variants on chromosomes 1 to 21. The result has been adjusted for the length of genome, i.e. adjusted GWFPR = GWFPR * length (genome) / length (chromosomes 1 to 21). ) is an example generated from simulations (simulating two rare variants with expected r 2 value of ~0.45), which demonstrates that the distribution of LD r 2 in a sample of 20,000 individuals is almost identical to that in a sample of 3,600 individuals at the same MAC threshold. This suggests that the sampling variation of LD r 2 depends on MAC, which is a product of MAF and sample size. We investigated the extent to which our result was affected by the sampling variation in LD by re-calculating the mapping precision for rare variants with MAC > 4 in the UK10K data. The result remained almost exactly the same (panel c), suggesting that the low mapping precision of GWAS for rare variants using imputed data is not driven by the sampling variation in LD. Note that the purpose of this analysis is to quantify the proportion of genome-wide significant top variants within a given physical distance of the corresponding causal variants. We therefore assigned a relatively large effect size to the simulated causal variant so that the variance explained by each causal variant (q 2 ) was 2%. The expected chi-squared value for the causal variant is ~75 given q 2 = 2% and n = 3,642, which is much larger than the genomewide significant level (corresponding to a chi-squared value of about 30). This explains why the power for GWAS using UK10K-WGS data is almost 100% (first row of the table). 
